Assuntos
Diabetes Mellitus , Retinopatia Diabética , Edema Macular , Miopia Degenerativa , Esclerite , Humanos , Edema Macular/diagnóstico , Edema Macular/tratamento farmacológico , Edema Macular/etiologia , Retinopatia Diabética/complicações , Retinopatia Diabética/diagnóstico , Miopia Degenerativa/complicações , Tomografia de Coerência Óptica , Biomarcadores , Tomada de DecisõesAssuntos
Membrana Epirretiniana , Perfurações Retinianas , Humanos , Perfurações Retinianas/diagnóstico , Perfurações Retinianas/etiologia , Perfurações Retinianas/cirurgia , Hemorragia Vítrea , Retina , Membrana Epirretiniana/cirurgia , Lasers , Vitrectomia , Membrana Basal , Estudos Retrospectivos , Tomografia de Coerência ÓpticaAssuntos
Oftalmopatias , Nevo Pigmentado , Humanos , Vitrectomia , Corpo Vítreo , Recurvamento da Esclera , Nevo Pigmentado/cirurgiaAssuntos
Diabetes Mellitus , Retinopatia Diabética , Síndrome de Waardenburg , Humanos , VitrectomiaAssuntos
Malformações Arteriovenosas , Membrana Epirretiniana , Perfurações Retinianas , Humanos , Vitrectomia/métodos , Perfurações Retinianas/diagnóstico , Perfurações Retinianas/cirurgia , Membrana Epirretiniana/cirurgia , Resultado do Tratamento , Membrana Basal/cirurgia , Estudos Retrospectivos , Tomografia de Coerência ÓpticaAssuntos
Miopia , Descolamento Retiniano , Perfurações Retinianas , Humanos , Perfurações Retinianas/diagnóstico , Perfurações Retinianas/etiologia , Perfurações Retinianas/cirurgia , Epitélio Pigmentado da Retina , Descolamento Retiniano/diagnóstico , Descolamento Retiniano/etiologia , Descolamento Retiniano/cirurgia , Angiofluoresceinografia , Vitrectomia , Tomografia de Coerência Óptica , Miopia/complicações , Peptídeos e Proteínas de Sinalização IntercelularAssuntos
Macroaneurisma Arterial Retiniano , Oclusão da Artéria Retiniana , Artéria Retiniana , Uveíte , Cirurgia Vitreorretiniana , Humanos , Macroaneurisma Arterial Retiniano/complicações , Hemorragia Retiniana , Retina , Oclusão da Artéria Retiniana/complicações , Oclusão da Artéria Retiniana/diagnóstico , Uveíte/complicações , AngiofluoresceinografiaRESUMO
BACKGROUND AND OBJECTIVE: The aim of this study was to evaluate the interobserver agreement of the myopic traction maculopathy (MTM) staging system (MSS). PATIENTS AND METHODS: Each observer was asked to look at the MSS Table and then identify, in each optical coherence tomography scan, one among four stages of MTM in the retina, one among three stages in the fovea, and, as secondary findings, the presence or absence of an outer lamellar macular hole and the presence or absence of epiretinal abnormalities. The interobserver agreement value was calculated using the Gwet's AC1 unweighted and AC2 weighted statistics. The outcomes were interpreted as poor (<0.00), slight (0.00 to 0.20), fair (0.21 to 0.40), moderate (0.41 to 0.60), substantial (0.61 to 0.80), or almost perfect (0.81 to 1.00) agreement. RESULTS: The agreement, among 65 participants, was 0.62 (AC1) and 0.77 (AC2) for the retina stage; 0.63 (AC1) and 0.81 (AC2) for the fovea stage; 0.56 (AC1) for the outer lamellar macular hole; and 0.26 (AC1) for epiretinal abnormalities. CONCLUSION: The MSS is highly reproducible and helps ophthalmologists to share information on MTM in a more accurate and reliable way. [Ophthalmic Surg Lasers Imaging Retina 2023;54(3):153-157.].
Assuntos
Degeneração Macular , Miopia Degenerativa , Perfurações Retinianas , Humanos , Perfurações Retinianas/diagnóstico , Perfurações Retinianas/complicações , Tração , Retina , Fóvea Central , Tomografia de Coerência Óptica/métodos , Degeneração Macular/complicações , Estudos Retrospectivos , Miopia Degenerativa/complicações , Miopia Degenerativa/diagnósticoRESUMO
PURPOSE: The complement pathway may play a key role in the pathogenesis of age-related macular degeneration (AMD). The safety and efficacy of avacincaptad pegol (Zimura, IVERIC bio Inc, New York, NY), a C5 inhibitor, were assessed in participants with geographic atrophy (GA) secondary to AMD (GATHER1 Study). DESIGN: International, prospective, randomized, double-masked, sham-controlled, pivotal phase 2/3 clinical trial. PARTICIPANTS: A total of 286 participants with GA secondary to AMD. MAIN OUTCOME MEASURES: The primary efficacy endpoint was the mean rate of change in GA over 12 months measured by fundus autofluorescence (FAF) at 3 timepoints: baseline, month 6, and month 12. RESULTS: The reduction in the mean rate of GA growth (square root transformation) over 12 months was 27.4% (P = 0.0072) for the avacincaptad pegol 2 mg cohort and 27.8% (P = 0.0051) for the avacincaptad pegol 4 mg cohort compared with their corresponding sham cohorts. The results for both dose groups were statistically significant. Avacincaptad pegol was generally well tolerated after monthly administration over 12 months. There were no avacincaptad pegol-related adverse events (AEs) or inflammation. Further, there were no ocular serious AEs (SAEs) and no cases of endophthalmitis. The most frequent ocular AEs were related to the injection procedure. CONCLUSIONS: Intravitreal administration of avacincaptad pegol 2 mg and 4 mg led to a significant reduction of GA growth in eyes with AMD over a 12-month period. Because C5 inhibition theoretically preserves C3 activity, it may offer additional safety advantages. A second confirmatory pivotal clinical trial is underway to confirm the efficacy and safety of avacincaptad pegol in slowing the GA growth (GATHER2 Study).
